Sewanti Limaye
Overview
Explore the profile of Sewanti Limaye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
2.
Limaye S, Deshmukh J, Rohatagi N, Prabhash K, Rauthan A, Singh S, et al.
J Immunother Precis Oncol
. 2025 Jan;
8(1):55-63.
PMID: 39811425
Biologic factors limiting responsiveness to matched targeted therapies include genomic heterogeneity and complexity. Advanced tumors with unique molecular profiles can be studied by comprehensive genomic profiling (CGP) and enhance patient...
3.
Limaye S, Menon M, Singh S, Kataria P, Shreenivas A, Datar R, et al.
J Immunother Precis Oncol
. 2024 Sep;
7(3):171-177.
PMID: 39220001
No abstract available.
4.
Jha P, Joshi A, Mishra R, Biswal R, Kulkarni P, Limaye S, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):e420-e430.e20.
PMID: 39129089
Background: The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights...
5.
Crook T, Patil D, Nagarkar R, Gaya A, Plowman N, Limaye S, et al.
Front Mol Med
. 2024 Aug;
1:749283.
PMID: 39087078
Angiogenic factors are commonly activated in solid tumors and present a viable therapeutic target. However, anticancer treatment with angiogenesis inhibitors (AGI) is limited to a few cancers, mostly as monotherapy...
6.
Mankan A, Shankar A, Limaye S, Ajaikumar B, Nachane P, Singh N, et al.
JCO Glob Oncol
. 2024 Jun;
10:e2300405.
PMID: 38870438
Executing global clinical trials for cancer is a long, expensive, and complex undertaking. While selecting countries global studies, sponsors must consider several aspects including patient pool, quality of trained investigators,...
7.
Schaffrin-Nabe D, Josten-Nabe A, Tannapfel A, Uhl W, Garmer M, Kurzrock R, et al.
Front Oncol
. 2024 May;
14:1395618.
PMID: 38764581
Despite multiple recent advances in systemic therapy for metastatic breast cancer, cases which display suboptimal response to guideline-driven treatment are frequently seen in the clinic. Effective options for such patients...
8.
Gaya A, Rohatgi N, Limaye S, Shreenivas A, Ajami R, Akolkar D, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611078
Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate the performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers (PBC)....
9.
ONeill K, Syed N, Crook T, Dubey S, Potharaju M, Limaye S, et al.
Int J Cancer
. 2023 Dec;
154(7):1298-1308.
PMID: 38146864
Here, we describe a blood test for the detection of glial malignancies (GLI-M) based on the identification of circulating glial cells (CGCs). The test is highly specific for GLI-M and...
10.
Monk B, Toita T, Wu X, Vazquez Limon J, Tarnawski R, Mandai M, et al.
Lancet Oncol
. 2023 Dec;
24(12):1334-1348.
PMID: 38039991
Background: Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years....